Advertisement
Advertisement
BMY
Bristol-Myers Squibb Co.
62.68
USDSponsored
+1.29
+2.10%
Oct 30, 13:13 UTC -4
Open
Bristol-Myers Squibb Co. (BMY) Earnings
BMY Earnings Reports
Positive Surprise Ratio
BMY beat 38 of 43 last estimates.
88%
Next Report
Date of Next Report
Feb 03, 2027
Estimate for Q4 26 (Revenue/ EPS)
$12.85B
/$1.64
Implied change from Q3 26 (Revenue/ EPS)
-1.70%
/+21.48%
Implied change from Q4 25 (Revenue/ EPS)
+2.75%
/+30.16%
Bristol-Myers Squibb Co. earnings per share and revenue
On Oct 29, 2026, BMY reported earnings of 1.35 USD per share (EPS) for Q3 26, beating the estimate of 1.20 USD, resulting in a 11.66% surprise. Revenue reached 13.07 billion, compared to an expected 12.87 billion, with a 1.58% difference. The market reacted with a +1.35% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 1.64 USD, with revenue projected to reach 12.85 billion USD, implying an increase of 21.48% EPS, and decrease of -1.70% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Regeneron Pharmaceuticals Inc
Report Date
Oct 30, 2026 For Q3 26
Estimate
$16.47
Actual
$20.07
Surprise
+21.79%
Illumina Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.38
Actual
$1.44
Surprise
+4.18%
Insmed, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.46
Surprise
-19.82%
Incyte Genomics Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$3.92
Actual
-$3.60
Surprise
+8.33%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Exelixis Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.81
Actual
$0.94
Surprise
+15.64%
Kymera Therapeutics, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$1.29
Actual
-$1.32
Surprise
-2.17%
Ligand Pharmaceuticals Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.42
Actual
$2.67
Surprise
+9.91%
PTC Therapeutics, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.34
Actual
$0.61
Surprise
+75.59%
NovoCure Limited Ordinary Shares
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.09
Surprise
+63.88%
FAQ
What were Bristol-Myers Squibb Co.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Bristol-Myers Squibb Co. reported EPS of $1.35, beating estimates by 11.66%, and revenue of $13.07B, 1.58% above expectations.
How did the market react to Bristol-Myers Squibb Co.'s Q3 2026 earnings?
The stock price moved up 1.35%, changed from $60.57 before the earnings release to $61.39 the day after.
When is Bristol-Myers Squibb Co. expected to report next?
The next earning report is scheduled for Feb 03, 2027.
What are the forecasts for Bristol-Myers Squibb Co.'s next earnings report?
Based on --
analysts, Bristol-Myers Squibb Co. is expected to report EPS of $1.64 and revenue of $12.85B for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.